


# Advanced Basal Cell Carcinoma:

Current and  
Emerging  
Targeted Therapies



The **PA Academy of Dermatology** cordially invites you to attend a CME-certified, MOC-eligible live webinar entitled, **Advanced Basal Cell Carcinoma: What Dermatologists Need to Know About Current and Emerging Targeted Therapies**, held live online! This activity will provide these clinicians with updates on treatment options, along with reinforcing the roles that dermatologists serve, e.g. monitoring and managing side effects of therapy and ensuring effective multidisciplinary management, in the care of patients with advanced BCC.

**Date:** Tuesday, November 16, 2021

**Time:** 6:00 PM – 7:00 PM EASTERN

**Location:** Live Online!

**For full accreditation information and to register, visit:**

[www.rockpointe.com/BCCRegistration](http://www.rockpointe.com/BCCRegistration)

**Suggested Browsers:** Apple Safari, Google Chrome, or Mozilla Firefox

## PROGRAM FACULTY



**Andrew C. Krakowski, MD**  
Network Chair of Dermatology  
Program Director for the Residency in  
Dermatology  
St. Luke's University Health Network  
Bethlehem, PA



**Melissa Wilson, MD, PhD**  
Medical Oncology Fellowship Program  
Director/Melanoma Program Director  
St. Luke's Cancer Center –  
St. Luke's University Health Network  
Easton, PA

**PHYSICIAN ACCREDITATION STATEMENT** – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

**PHYSICIAN CREDIT DESIGNATION STATEMENT** – The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



**ABIM MOC RECOGNITION STATEMENT** – Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you **MUST** pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

**AMERICAN BOARD OF DERMATOLOGY MOC INFORMATION** – Dermatologists certified by the American Board of Dermatology (ABD) must earn a minimum of 25 hours of *AMA PRA Category 1 Credits*<sup>™</sup> annually. Half of these credits must be Dermatology practice-specific CME credits from accredited organizations in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board certified dermatologists in contributing towards this MOC requirement set forth by the ABD.

**FEE AND RECEIVING CME CREDIT** - There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

For questions regarding CME credit or the evaluation, please email [contact@potomacme.org](mailto:contact@potomacme.org).

Disclosures will be made known to participants before the activity.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.